Piyush Goyal has called on Swiss firms to scale up their investments in India, positioning the country as a strategic base for manufacturing, innovation, and global market access.

AR1001 is a novel, disease-modifying, once-daily oral phosphodiesterase-5 (PDE5) inhibitor currently being studied in a global Phase 3 clinical trial (POLARIS-AD) for the treatment of early-stage ...

Piyush Goyal announces India's trade agreement with the European Free Trade Association will be effective in September. The ...

In this article, GlobalData examines key reimbursement trends that reflect the current delays to patient access across the ...

Swissport has reinforced its logistics operations at EuroAirport Basel–Mulhouse–Freiburg with the addition of 800 square ...

Multi-tool knives may be smaller than other knives, but that doesn't mean you can't sharpen them using a leather strap just ...

For decades, things went well for Bellevue Group. But now the sector weakness in biotechs could lead to losses.

Azafaros, a clinical-stage biotechnology company developing novel therapies for rare lysosomal storage disorders (LSDs), today announced that it will present at the 2025 BIO International Convention ...

Drugmakers and contract manufacturers are responding to the booming demand for antibody-drug conjugates, with multiple ...

China has leaped from fast follower to global pioneer in drug discovery and development. We believe that Chinese companies ...

A dual-track approach has gained momentum for biotech companies as capital markets remain volatile and acquirers become more ...

Swissport is expanding its presence at EuroAirport Basel Airport with the addition of 800 sq m of new freight space in ...